Genmab A/S Stock

Genmab A/S Gross Margin

The Gross Margin of Genmab A/S (GMAB.CO) as of Aug 5, 2026 is 93.60 %. In the previous year, Gross Margin was 95.42 % — a change of -1.91% (lower).

Gross Margin

93.60 %

YoY

-1.91%

Last updated:

Gross Margin of Genmab A/S is 2026 93.60 % . Gross Margin of Genmab A/S was 2025 95.42 % . It decreases by -1.91% lower compared to the previous year.

For Genmab A/S, the gross margin of 93.6% is down versus 100.0% a few years ago.

Access this data via the Eulerpool API
Get Free API Key

Genmab A/S Stock analysis

What does Genmab A/S do? Genmab A/S is a Danish biotechnology company specializing in the discovery and development of antibody therapies for cancer and other serious diseases. The company was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab A/S stock

Gross Margin of Genmab A/S is 93.60 % in 2026.

Gross Margin of Genmab A/S changed from 95.42 % to 93.60 %, representing a -1.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Genmab A/S since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Genmab A/S with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API
Get Free API Key

Margins — Genmab A/S

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Genmab A/S